A Hit and a Miss for Merck’s Keytruda

A Hit and a Miss for Merck’s Keytruda

Source: 
BioSpace
snippet: 

Merck posted a rare defeat Wednesday for its blockbuster Keytruda (pembrolizumab) in prostate cancer while simultaneously announcing a victory in biliary tract cancer.